Exciting Perspectives on Treating Psoriatic Arthritis: Exploring Personalized Treatment Strategies


A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 6, 2018 to July 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Lilly USA LLC and Novartis Pharmaceuticals

Description:
Psoriatic arthritis (PsA) is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations that often lead to extreme pain and joint damage that may affect a patient’s quality of life, physical function, and ability to work. This potentially disfiguring condition remains underdiagnosed and symptoms include fatigue, joint inflammation, and potentially progressive, irreversible joint damage. Diagnosing PsA can be very complex and may be easier to confirm if psoriasis coexists with symptoms of arthritis, however symptoms of PsA appear before symptoms of psoriasis. A careful medical history, physical examination, blood tests, magnetic resonance imaging (MRI), and x-rays of the involved joints along with a dermatologic evaluation may be used to diagnose PsA. The goals of treatment for PsA include early diagnosis, with early aggressive treatment aimed at limiting joint damage and clearing psoriasis. The treatment recommendations for PsA include the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and traditional disease-modifying antirheumatic drugs (DMARDs). Fortunately, novel biologic treatments have been developed and proven to stop joint damage, pain, and swelling in moderate to severe disease. These treatments include adalimumab, etanercept, golimumab, certolizumab, and infliximab. Other biologics have been produced that help block proteins IL-12, IL-23, and IL-17. These biologics reduce inflammation, are given by a subcutaneous injection, and are producing results that treat the skin as well as arthritis.

Upon Completion of this activity, participants will be able to:

  • Analyze the mechanisms of action, efficacy, and safety profiles of current and emerging treatment options for psoriatic arthritis, including investigational agents

  • Assess the latest developments in biologic therapies in the treatment of psoriatic arthritis

  • Describe the advanced strategies for accurate diagnosis and patient monitoring

  • Identify personalized treatment plans and the integration of patient preferences for psoriatic arthritis to maximize clinical and functional outcomes

  • Discuss the common comorbidities associated with psoriatic arthritis
     

Faculty: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist Hospital for Special Surgery

Disclosure:

Dr. Gibofsky serves on an advisory board for AbbVie, Celgene and Pfizer. He serves as a consultant for AbbVie, Celgene, Lilly and Pfizer. He serves on the speaker's bureau for AbbVie, Celgene and Pfizer. He owns stock in AbbVie, Amgen, BMS, Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Lilly USA LLC and Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue